Kidney Cancer News, Research Articles | ED Treatment Studies

Kidney Cancer

KIDNEY CANCER

Time on mRCC Drug Linked to Survival

Within the first 2 lines of treatment, patients with metastatic renal cell carcinoma who remain on a drug for at least 3 months have longer overall survival than those who do not, a study found.
Next post in Kidney Cancer